Parameters of ploidity and kinetics of cell cycle in bone marrow samples of lymphoma patients were studied by flow cytometry. These parameters were compared to the lymphoma prognostic criteria: disease stage, levels of lactate dehydrogenase, sed rate test, B-symptoms, Bcl-2, Ki-67 etc. Analysis of the results shows, that bone marrow lesions in primary tumors are characterized by a statistically significant increase in Bcl2-expressing cells and percentage of cells in G0-1 stage of the cell cycle, as well as decrease in percentage of cells in G2М and S stages and percentage of cells of the proliferative pool S+G2M, (G2M+S) / G0-1 compared to non-affected hematopoietic cells. Primary and recurrent lymphomas with bone marrow lesions are characterized by significant variability in cell cycle parameters describing proliferative activity of mononuclear cells combined with inefficiency of hematopoiesis. Marker cytokinetic parameters can be used as prognostic criteria for overall and relapse-free survival of patients with lymphomas.

The authors analysed the efficacy and safety of Nab-paclitaxel (Nab-R) monotherapy in patients with metastatic breast cancer with visceral crisis (VC) in the second- and further-line chemotherapy. The objective response rate (ORR) was 35.3% (6 of 17 persons). The most frequent side effects were general weakness, nausea, symptoms of peripheral neuropathy. The degree of toxicity did not exceed 1–2 in 60% of cases. The median time to progression was 7.8 months. (95% CI 6–10.6). The median overall survival for patients with VC was 14.9 months. (95% CI 12.0–16.9). Efficacy and controlled toxicity of Nab-P allows its use in pre-treated patients, including ones with VC.